Bispecific ADCs YH012, YH013

YH012 and YH013 are two bispecific ADCs developed using our RenLite platform, which are intended for the treatment of solid tumor. YH012 and YH013 are currently at the discovery stage.

AACR 2022 poster: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

Contact us for partnership: [email protected]

Back to top